Trial Profile
A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2022
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 21 May 2021 Status changed from active, no longer recruiting to completed.
- 02 Feb 2021 Results (data cutoff date: 31 May 2020) published in the Journal of Thoracic Oncology
- 08 Sep 2020 Planned End Date changed from 1 Dec 2020 to 1 Sep 2022.